Navigation Links
Regeneron Announces Presentation at the Morgan Stanley Global Healthcare Conference
Date:9/3/2010

TARRYTOWN, N.Y., Sept. 3 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) will webcast its presentation at the Morgan Stanley Global Healthcare Conference on Monday, September 13, 2010.  The presentation is scheduled for 1:00 p.m. Eastern Time.  The session may be accessed through the Company's web site, www.regeneron.com, on the Investor Relations page.  An archived version of the presentation will be available after the live webcast through October 13, 2010.  

Regeneron is a fully integrated biopharmaceutical company that discovers, develops, and commercializes medicines for the treatment of serious medical conditions.  In addition to ARCALYST® (rilonacept) Injection for Subcutaneous Use, its first commercialized product, Regeneron has therapeutic candidates in Phase 3 clinical trials for the potential treatment of gout, diseases of the eye (wet age-related macular degeneration and central retinal vein occlusion), and certain cancers.  Additional therapeutic candidates developed from proprietary Regeneron technologies for creating fully human monoclonal antibodies are in earlier stage development programs in rheumatoid arthritis and other inflammatory conditions, pain, cholesterol reduction, allergic and immune conditions and cancer.  Additional information about Regeneron and recent news releases are available on Regeneron's web site at www.regeneron.com. Contact Information:Michael Aberman, M.D.Investor Relations914.345.7799michael.aberman@regeneron.comPeter DworkinCorporate Communications914.345.7800peter.dworkin@regeneron.com
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Regeneron Announces Presentation at the Deutsche Bank 2009 Biotech Boston Confab
2. BioMed Realty Trust Signs New Lease With Regeneron Pharmaceuticals for 131,000 Square Feet at Landmark
3. Sanofi-aventis and Regeneron Expand Strategic Antibody Collaboration
4. Regeneron Reports Third Quarter 2009 Financial and Operating Results
5. Regeneron Announces Presentation at the 18th Annual Credit Suisse Healthcare Conference
6. Enrollment Completed in Regeneron and Bayer HealthCare Phase 3 Studies of VEGF Trap-Eye in Neovascular Age-Related Macular Degeneration (Wet AMD)
7. Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion
8. Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration
9. ForteBio Announces Launch of Protein G Biosensor for Use on Companys Octet® Instruments
10. Optimer Pharmaceuticals Announces Presentations of Additional Fidaxomicin Phase 3 Data at Upcoming ICAAC Annual Meeting
11. Nutraceutical Leader Announces Internal Promotions of Key Personnel
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... , March 23, 2017 ... 2021, a latest research report. The global vagus nerve ... shift of surgeons focus toward minimally invasive VNS procedures. ... limited to few developed countries having high standards of ... ...
(Date:3/22/2017)... , 22 de marzo de 2017   ... líder de soluciones de productos y servicios para ... que ha adquirido EPL Archives, Inc., una organización ... clientes en todo el ciclo de vida de ... una muestra de archivo, almacenamiento de documentos y ...
(Date:3/22/2017)... , Mar. 22, 2017 Research and ... Devices Market Analysis & Trends - Industry Forecast to 2025" ... ... grow at a CAGR of around 10.9% over the next decade ... industry report analyzes the market estimates and forecasts for all the ...
Breaking Medicine Technology:
(Date:3/22/2017)... ... March 23, 2017 , ... Catalent Pharma ... drugs, biologics and consumer health products, today announced that it had won the ... place at the Suntec Singapore International Exhibition & Convention Centre, Singapore. The award ...
(Date:3/22/2017)... ... March 22, 2017 , ... ... Area providing insurance assistance, financial planning, and related services to residents of the ... to promote awareness of threatened species and wild lands. , Endangered Species International ...
(Date:3/22/2017)... CA (PRWEB) , ... March 22, 2017 , ... ... Jose, Santa Cruz and Milpitas with a robust, ongoing community enrichment program, has ... (FSH), a nonprofit organization which has provided for the critical needs of homeless ...
(Date:3/22/2017)... ... March 22, 2017 , ... ... a PCSK9 inhibitor prior authorization (PA) form for prescribers to improve patients’ access ... of the helpful tools published as part of the article entitled “PCSK9 ...
(Date:3/22/2017)... ... 2017 , ... Old School Labs™, makers of the best-selling Vintage line of ... Ambassador. Theophane, who trained with Floyd Mayweather, made his professional debut in London in ... an impressive number of wins in contests in Britain, Germany and the U.S. ...
Breaking Medicine News(10 mins):